An Enantiomer-Enantiomer Interaction of (S)-and (R) Background Therapy with racemic compounds produces effects that can be attributed to both (S)-and (R)-enantiomers. Here we have tested the hypothesis that an enantiomer-enantiomer interaction would modulate the effects of treatment with a racemate, the antiarrhythmic propafenone. Previous studies have shown that while the enantiomers of propafenone exert similar sodium channel-blocking (QRS widening) effects, it is the (S)-enantiomer that produces (-blockade; moreover, we have demonstrated recently that (R)-propafenone inhibits the metabolism of (S)-propafenone in vitro.
Methods and Results This single-blind, randomized study compared the effects of (RIS)-, (S)-, and (R)-propafenone (150 mg q 6 hours for 4 days) and placebo on QRS duration (AQRS) and on maximum exercise heart rate (,HR.DI), an index of (-blockade. The clearance of (S)-propafenone was significantly lower (-55±24%, P<.001) during treatment with (R/S)-propafenone than with the (S)-enantiomer alone, and AHR.,,I was significantly altered during (R/S)-propafenone (-8.8±6.6 beats per minute; P<.01) and during (S)-propafenone (-4.3±4.8 beats per minute; P<.01) but not during (R)-propafenone (-1.8±6.4 beats per minute) or placebo (0.3±7.1 beats per minute). In contrast, (RIS)-, (S)-, and (R)-propafenone all prolonged QRS compared with placebo.
Conclsions These data indicate that (R)-propafenone impairs the disposition of (S)-propafenone in humans. As a result, the 3-blocking effects of 150 mg of racemic propafenone (75 mg of the [Sl-enantiomer) were more pronounced than those of 150 mg of (S)-propafenone alone. Thus, the effects of racemic drug therapy are not necessarily those predicted by summation of the effects of the individual enan 
Study Design
The study design was single blind and placebo controlled, with a random order of the four treatments: (R/S)-propafenone, (S)-propafenone, (R)-propafenone (150 mg q 6 hours for 4 days), and placebo (1 tablet q 6 hours for 4 days). There was a drug-free interval of at least 7 days between each study part. Propafenone enantiomers were separated from racemic propafenone via diastereomeric salt formation using ditoluyltartaric acid as a resolving agent and 2-butanone/water (98:2, vol/vol) as solvent for recrystallization.14 The enantiomeric purity determined by chiral high-performance liquid chromatography (HPLC) using a Daicel Chiralpak AD column as stationary phasel5 was more than 99%. Racemic propafenone was a generous gift from Knoll AG, Ludwigshafen, Germany.
Blood samples were taken before the first dose and on day 4 before administration of the morning dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, and 24 hours. Urine was collected for 6 hours after the last dose (0 to 6 hours on day 4). In each arm, maximum exercise heart rate (HR.) was determined using the method described by Bailey et al (bicycle ergometer ERG 550 PS; Schiller AG)16 before the first administration and on day 4 before administration of the morning dose and at 3, 6, and 24 hours. ECGs (12-channel ECG Cardiovit CS-6/12; Schiller AG) and blood pressure (automated Dinamap 1846SX; Critikon GmbH) were recorded at the same time.
Determination of Propafenone, Its Enantiomers, and Metabolites
After administration of the individual enantiomers, a nonstereoselective HPLC assay was used for quantification of plasma propafenone.17 In brief, 1 mL of plasma was spiked with 250 ng of internal standard [2'-(2-hydroxy-3-ethylaminopropoxy)-3-phenylpropiophenone hydrochloride], adjusted to pH 9 with 500 ,uL of ammonium hydroxide/ammonium chloride buffer (1 mmol/L), and extracted with 5 mL of dichloromethane. After centrifugation, the organic phase was evaporated to dryness with a gentle stream of nitrogen. The residue was dissolved in 50 ,uL of mobile phase, injected into the HPLC system, and quantified with UV detection (A=220 nm).
A 5-,gm Cl8 reverse-phase column (15 x0 
Discussion
These pharmacokinetic data indicate that the clearance of the (S)-enantiomer of propafenone is considerably reduced when it is administered with the (R)-enantiomer in the racemic mixture. This reduced clearance resulted in significantly higher plasma concentrations of (S)-propafenone after administration of 150 mg of racemate than would be predicted based on pharmacokinetic data obtained after administration of 150 mg of (S)-enantiomer. Steady-state plasma concentrations after administration of 150 mg of (S)-propafenone averaged 196±105 ng/mL. Thus, one would expect mean plasma concentrations after administration of racemate, which contains only 75 mg of the /-blocking (S)-enantiomer, to be no higher than 100 ng/mL. However, we observed plasma concentrations of 224±76 ng/mL, indicating that clearance of (S)-propafenone is reduced by 55 ±24% after administration of racemate.
The question arises as to the mechanism underlying this reduced clearance of (S)-propafenone in presence of the (R)-enantiomer. Our recent experiments in human liver microsomes indicated that cytochrome P450 2D6-mediated 5-hydroxylation of (S)-propafenone, which represents the major metabolic route in vivo, is inhibited by the (R)-enantiomer in a competitive manner. 8 Accordingly, we found a prolonged elimination half-life of (S)-propafenone after administration of racemate when compared with the (S)-enantiomer alone, which is compatible with reduced clearance of (S)-enantiomer due to the interaction with (R)-propafenone while volume of distribution remains constant. Another mechanism for this enantiomer-enantiomer interaction could be an interconversion from (R)-propafenone to (S)-enantiomer (such transformation has been described for 2-arylpropionic acid21). However, we observed no formation of the (S)-propafenone after administration of the (R)-enantiomer and vice versa; therefore, this possibility can be excluded. Enantioselectivity in absorption as a mechanism for the interaction appears to be unlikely, given the lack of difference in cumulative urinary excretion. The different clearance data after administration of the enantiomers are in agreement with a previous report by Brode et The results obtained for prolongation of QRS interval by propafenone and its enantiomers stand in contrast to the situation described for 1-blockade. In vitro, racemate and the 5-hydroxy-metabolite are equipotent in terms of electrophysiological activity, and other studies have shown the enantiomers to be equipotent.5,7,29,30 Therefore, a metabolic interaction between the enantiomers is predicted to be of little relevance for electrophysiological effects of propafenone, the hallmark of which is prolongation of the QRS interval. Indeed, no differences were found between QRS prolongation by both enantiomers and the racemate (Fig 2) . Again, these results highlight the fact that the consequences of interactions between enantiomers of a racemate depend on the individual pharmacological actions of the respective enantiomers. Moreover, as shown in the case of propafenone, these consequences pertain to the particular pharmacological activity being assessed and can be different for different types of drug action.
In summary, we present the first detailed evidence for an enantiomer-enantiomer interaction, which has implications for the effects of a racemic drug in humans. Previous reports concerning this type of interaction have been restricted to in vitro data.31-34 Our data demonstrate that the pharmacological activity and toxicity profile of a racemate may be modulated by an enantiomer-enantiomer interaction. Therefore, the strategy of developing homochiral compounds from currently available racemates may not necessarily lead to drugs with target pharmacological effects. Our data indicate the need to consider enantiomer-enantiomer interactions in the evaluation of the pharmacological effects of any racemate.
